Functional assessment of antibody oxidation by native mass spectrometry

mAbs

Volumn 7, Issue 5, 2015, Pages 891-900

  Haberger, Markus ^a   Heidenreich, Anna Katharina ^a   Schlothauer, Tilman ^a   Hook, Michaela ^a   Gassner, Jana ^a   Bomans, Katrin ^a   Yegres, Michelle ^a   Zwick, Adrian ^b   Zimmermann, Boris ^a   Wegele, Harald ^a   Bonnington, Lea ^a   Reusch, Dietmar ^a   Bulau, Patrick ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Critical quality attributes; Native mass spectrometry; Neonatal Fc receptor; Oxidation; Protein degradation; Recombinant antibodies

Indexed keywords

ASPARAGINE; ASPARTIC ACID; FC RECEPTOR; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G1; SCATTER FACTOR RECEPTOR; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; CHO CELL LINE; DATA ANALYSIS; DEAMINATION; FUNCTIONAL ASSESSMENT; ISOMERIZATION; MASS SPECTROMETRY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PEPTIDE MAPPING; PROTEIN EXPRESSION; SIZE EXCLUSION CHROMATOGRAPHY; SURFACE PLASMON RESONANCE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET SPECTROPHOTOMETRY; CHEMISTRY; HUMAN; LIQUID CHROMATOGRAPHY; METABOLISM; OXIDATION REDUCTION REACTION; PROCEDURES;

ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, LIQUID; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN G; MASS SPECTROMETRY; OXIDATION-REDUCTION; PEPTIDE MAPPING; RECEPTORS, FC; SURFACE PLASMON RESONANCE;

EID: 84953382225     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1052199     Document Type: Article

References (54)

1. Beck A, Carter PJ, Gerber HP, Lugovskoy AA, Wurch T, Junutula JR, Kontermann RE, Mabry R. 8 (th) Annual European antibody congress 2012: november 27-28, 2012, Geneva, Switzerland. mAbs 2013; 5:339-57; PMID:23493119.
2. Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier-Cianferani S. Characterization of therapeutic antibodies and related products. Anal Chem 2013; 85:715-36; PMID:23134362; http://dx. doi. org/ 10. 1021/ac3032355.
3. Harris RJ. Heterogeneity of recombinant antibodies: linking structure to function. Dev Biol (Basel) 2005; 122:117-27; PMID:16375256.
4. Hovorka S, Schoneich C. Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition. J Pharm Sci 2001; 90:253-69; PMID:11170019; http:// dx. doi. org/10. 1002/1520-6017(200103)90:3%3c253:: AID-JPS1%3e3. 0. CO;2-W.
5. Ji JA, Zhang B, Cheng W, Wang YJ. Methionine, tryptophan, and histidine oxidation in a model protein, PTH: mechanisms and stabilization. J Pharm Sci 2009; 98:4485-500; PMID:19455640; http://dx. doi. org/ 10. 1002/jps. 21746.
6. Li S, Schoneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng 1995; 48:490-500; PMID:18623513; http://dx. doi. org/10. 1002/bit. 260480511.
7. Nguyen TH, Burnier J, Meng W. The kinetics of relaxin oxidation by hydrogen peroxide. Pharm Res 1993; 10:1563-71; PMID:8290468; http://dx. doi. org/ 10. 1023/A:1018908316698.
8. Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J Pharm Sci 2007; 96:1-26; PMID:16998873; http://dx. doi. org/10. 1002/jps. 20727.
9. Bertolotti-Ciarlet A, Wang W, Lownes R, Pristatsky P, Fang Y, McKelvey T, Li Y, Li Y, Drummond J, Prueksaritanont T, et al. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol Immunol 2009; 46:1878-82; PMID:19269032; http://dx. doi. org/10. 1016/j. molimm. 2009. 02. 002.
10. Hensel M, Steurer R, Fichtl J, Elger C, Wedekind F, Petzold A, Schlothauer T, Molhoj M, Reusch D, Bulau P. Identification of potential sites for tryptophan oxidation in recombinant antibodies using tert-butylhydroperoxide and quantitative LC-MS. PLoS One 2011; 6: e17708; PMID:21390239; http://dx. doi. org/10. 1371/ journal. pone. 0017708.
11. Houde D, Kauppinen P, Mhatre R, Lyubarskaya Y. Determination of protein oxidation by mass spectrometry and method transfer to quality control. J Chromatogr A 2006; 1123:189-98; PMID:16716331; http://dx. doi. org/10. 1016/j. chroma. 2006. 04. 046.
12. Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, Li L, Brems DN, Remmele RL Jr. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 2008; 47:5088-100; PMID:18407665; http://dx. doi. org/ 10. 1021/bi702238b.
13. Stracke J, Emrich T, Rueger P, Schlothauer T, Kling L, Knaupp A, Hertenberger H, Wolfert A, Spick C, Lau W, et al. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. mAbs 2014; 6:1229-42; PMID:25517308; http://dx. doi. org/10. 4161/ mabs. 29601.
14. Chumsae C, Gaza-Bulseco G, Sun J, Liu H. Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 850:285-94; PMID:17182291; http:// dx. doi. org/10. 1016/j. jchromb. 2006. 11. 050.
15. Liu H, Gaza-Bulseco G, Xiang T, Chumsae C. Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody. Mol Immunol 2008; 45:701-8; PMID:17719636; http:// dx. doi. org/10. 1016/j. molimm. 2007. 07. 012.
16. Shen JF, Kwong MY, Keck RG, Harris RJ. The application of tertbutylhydroperoxide oxidation to study sites of potential methionine oxidation in a recombinant antibody. In: Techniques in Protein Chemistry VII, D. R. Marshak (Ed.). Academic Press Inc; 1996:275-84.
17. Wei Z, Feng J, Lin HY, Mullapudi S, Bishop E, Tous GI, Casas-Finet J, Hakki F, Strouse R, Schenerman MA. Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus. Anal Chem 2007; 79:2797-805; PMID:17319649; http://dx. doi. org/10. 1021/ac062311j.
18. Lam XM, Yang JY, Cleland JL. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci 1997; 86:1250-5; PMID:9383735; http://dx. doi. org/ 10. 1021/js970143s.
19. Haberger M, Bomans K, Diepold K, Hook M, Gassner J, Schlothauer T, Zwick A, Spick C, Kepert JF, Hienz B, et al. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes. mAbs 2014; 6:327-39; PMID:24441081; http://dx. doi. org/ 10. 4161/mabs. 27876.
20. Davies KJ, Delsignore ME, Lin SW. Protein damage and degradation by oxygen radicals. II. Modification of amino acids. J Biol Chem 1987; 262:9902-7; PMID:3036876.
21. Uchida K, Enomoto N, Itakura K, Kawakishi S. The hydroxyl radical generated by an iron(II)/EDTA/ascorbate system preferentially attacks tryptophan residues of the protein. Agric Biol Chem 1989; 53:3285-92; http://dx. doi. org/10. 1271/bbb1961. 53. 3285.
22. Yang J, Wang S, Liu J, Raghani A. Determination of tryptophan oxidation of monoclonal antibody by reversed phase high performance liquid chromatography. J Chromatogr A 2007; 1156:174-82; PMID:17379231; http://dx. doi. org/10. 1016/j. chroma. 2007. 01. 140.
23. Loew C, Knoblich C, Fichtl J, Alt N, Diepold K, Bulau P, Goldbach P, Adler M, Mahler HC, Grauschopf U. Analytical protein a chromatography as a quantitative tool for the screening of methionine oxidation in monoclonal antibodies. J Pharm Sci 2012; 101:4248-57; PMID:22899501; http://dx. doi. org/10. 1002/ jps. 23286.
24. Schlothauer T, Rueger P, Stracke JO, Hertenberger H, Fingas F, Kling L, Emrich T, Drabner G, Seeber S, Auer J, et al. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. mAbs 2013; 5:576-86; PMID:23765230; http:// dx. doi. org/10. 4161/mabs. 24981.
25. Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, Prueksaritanont T, Ionescu R. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 2011; 48:860-6; PMID:21256596; http://dx. doi. org/10. 1016/j. molimm. 2010. 12. 009.
26. Diepold K, Bomans K, Wiedmann M, Zimmermann B, Petzold A, Schlothauer T, Mueller R, Moritz B, Stracke JO, Mølhøj M, et al. Simultaneous assessment of Asp isomerization and Asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures. PLoS One 2012; 7:e30295; PMID:22272329; http://dx. doi. org/10. 1371/journal. pone. 0030295.
27. Heck AJ. Native mass spectrometry: a bridge between interactomics and structural biology. Nat Methods 2008; 5:927-33; PMID:18974734; http://dx. doi. org/ 10. 1038/nmeth. 1265.
28. Jecklin MC, Schauer S, Dumelin CE, Zenobi R. Labelfree determination of protein-ligand binding constants using mass spectrometry and validation using surface plasmon resonance and isothermal titration calorimetry. J Mol Recognit 2009; 22:319-29; PMID:19373858; http://dx. doi. org/10. 1002/jmr. 951.
29. Beck A, Reichert JM. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. mAbs 2011; 3:415-6; PMID:21785279; http://dx. doi. org/10. 4161/mabs. 3. 5. 17334.
30. Beck A, Sanglier-Cianferani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012; 84:4637-46; PMID:22510259; http://dx. doi. org/ 10. 1021/ac3002885.
31. Konijnenberg A, Butterer A, Sobott F. Native ion mobility-mass spectrometry and related methods in structural biology. Biochim Biophys Acta 2013; 1834:1239-56; PMID:23246828; http://dx. doi. org/ 10. 1016/j. bbapap. 2012. 11. 013.
32. Rosati S, Thompson NJ, Barendregt A, Hendriks LJ, Bakker AB, de Kruif J, Throsby M, van Duijn E, Heck AJ. Qualitative and semiquantitative analysis of composite mixtures of antibodies by native mass spectrometry. Anal Chem 2012; 84:7227-32; PMID:22882109; http://dx. doi. org/10. 1021/ac301611d.
33. Rosati S, Yang Y, Barendregt A, Heck AJ. Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry. Nat Protoc 2014; 9:967-76; PMID:24675736; http://dx. doi. org/ 10. 1038/nprot. 2014. 057.
34. Sharon M, Robinson CV. The role of mass spectrometry in structure elucidation of dynamic protein complexes. Annu Rev Biochem 2007; 76:167-93; PMID:17328674; http://dx. doi. org/10. 1146/annurev. biochem. 76. 061005. 090816.
35. Thompson NJ, Hendriks LJ, de Kruif J, Throsby M, Heck AJ. Complex mixtures of antibodies generated from a single production qualitatively and quantitatively evaluated by native Orbitrap mass spectrometry. mAbs 2014; 6:197-203; PMID:24351421; http://dx. doi. org/10. 4161/mabs. 27126.
36. Thompson NJ, Rosati S, Heck AJ. Performing native mass spectrometry analysis on therapeutic antibodies. Methods 2014; 65:11-7; PMID:23688935; http://dx. doi. org/10. 1016/j. ymeth. 2013. 05. 003.
37. Thompson NJ, Rosati S, Rose RJ, Heck AJ. The impact of mass spectrometry on the study of intact antibodies: from post-translational modifications to structural analysis. Chem Commun 2013; 49:538-48; PMID:23183499; http://dx. doi. org/10. 1039/ C2CC36755F.
38. Zhang Z, Pan H, Chen X. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrom Rev 2009; 28:147-76; PMID:18720354; http://dx. doi. org/10. 1002/mas. 20190.
39. Atmanene C, Wagner-Rousset E, Malissard M, Chol B, Robert A, Corvaia N, Van Dorsselaer A, Beck A, Sanglier-Cianférani S. Extending mass spectrometry contribution to therapeutic monoclonal antibody lead optimization: characterization of immune complexes using noncovalent ESI-MS. Anal Chem 2009; 81:6364-73; PMID:19588976; http://dx. doi. org/ 10. 1021/ac9007557.
40. Kukrer B, Filipe V, van Duijn E, Kasper PT, Vreeken RJ, Heck AJ, Jiskoot W. Mass spectrometric analysis of intact human monoclonal antibody aggregates fractionated by size-exclusion chromatography. Pharm Res 2010; 27:2197-204; PMID:20680668; http://dx. doi. org/10. 1007/s11095-010-0224-5.
41. Rose RJ, Labrijn AF, van den Bremer ET, Loverix S, Lasters I, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW, Heck AJ. Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure 2011; 19:1274-82; PMID:21893287; http://dx. doi. org/10. 1016/j. str. 2011. 06. 016.
42. Martin WL, Bjorkman PJ. Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Biochemistry 1999; 38:12639-47; PMID:10504233; http://dx. doi. org/ 10. 1021/bi9913505.
43. Martin WL, West AP, Jr., Gan L, Bjorkman PJ. Crystal structure at 2. 8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 2001; 7:867-77; PMID:11336709; http://dx. doi. org/ 10. 1016/S1097-2765(01)00230-1.
44. Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dall'acqua WF. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol 2009; 46:1750-5; PMID:19250681; http://dx. doi. org/10. 1016/j. molimm. 2009. 01. 026.
45. Kabat EA, Wu TT, Perry H, Gottesman K, Foeller C. Sequences of proteins of immunological interest. NIH Publication 1991; No. 91-3242.
46. Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs 2015; 7:331-43; PMID:25658443.
47. Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, Goetsch L, Wurch T, Van Dorsselaer A, Corvaïa N. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008; 9:482-501; PMID:19075687; http://dx. doi. org/ 10. 2174/138920108786786411.
48. Burmeister WP, Gastinel LN, Simister NE, Blum ML, Bjorkman PJ. Crystal structure at 2. 2 A resolution of the MHC-related neonatal Fc receptor. Nature 1994; 372:336-43; PMID:7969491; http://dx. doi. org/ 10. 1038/372336a0.
49. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226-34; PMID:19247305; http://dx. doi. org/ 10. 1038/nrd2804.
50. Jefferis R. Glycosylation of antibody therapeutics: optimisation for purpose. Methods in molecular biology 2009; 483:223-38; PMID:19183902.
51. Jones EA, Waldmann TA. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest 1972; 51:2916-27; PMID:5080417; http://dx. doi. org/10. 1172/ JCI107116.
52. Wang S, Ionescu R, Peekhaus N, Leung JY, Ha S, Vlasak J. Separation of post-translational modifications in monoclonal antibodies by exploiting subtle conformational changes under mildly acidic conditions. J Chromatogr A 2010; 1217:6496-502; PMID:20828701; http://dx. doi. org/10. 1016/j. chroma. 2010. 08. 044.
53. Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. mAbs 2012; 4:653-63; PMID:22925968; http://dx. doi. org/10. 4161/mabs. 21379.
54. Wurch T, Pierre A, Depil S. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends Biotechnol 2012; 30:575-82; PMID:22944617; http://dx. doi. org/10. 1016/j. tibtech. 2012. 07. 006.